Temozolomide after radiation for low-grade brain tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding temozolomide chemotherapy after radiation helps control a type of low-grade brain tumor that was not fully removed. It may help reduce the chance the tumor comes back, compared with standard post-radiation care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 60 years old
- Your low-grade brain tumor (WHO grade 2) was not fully removed, and it’s in the upper brain
- Your general ability to function is reasonably good (Karnofsky score 60 or higher)
- Your blood counts and liver and kidney tests are adequate for chemotherapy
- You can understand the study and agree by signing consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a short course of chemotherapy (temozolomide) given before radiation can improve outcomes for people with newly diagnosed high-grade gliomas. It is designed for patients who are stable enough to delay starting radiation by a few weeks.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This study is testing a new way to target radiation for people with high-grade gliomas (aggressive brain tumors). The goal is to see if a more precise treatment plan can improve outcomes while keeping side effects low.
This trial compares standard radiation therapy versus radiation plus a chemotherapy medicine called temozolomide in people with a newly diagnosed low-grade (WHO grade II) brain glioma after surgery. It’s designed to see if adding temozolomide improves outcomes while managing side effects.
This study compares a standard radiation schedule versus a shorter, higher-dose radiation schedule, both with the chemotherapy medicine temozolomide, in older adults with newly diagnosed glioblastoma. It aims to see which approach works better and is practical for people age 70 and older.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Hear when a new Astrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.